Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 21Recruiting 12Not yet recruiting 4Completed 3Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Burkitt Lymphoma 1

Interventions

pembrolizumab 28Carboplatin 13Nivolumab 12Cisplatin 12atezolizumab 10Paclitaxel 10venetoclax 9Ipilimumab 9Radiotherapy 8Pemetrexed 8Docetaxel 8fludarabine 7durvalumab 7Specimen Handling 7Gemcitabine 7Cyclophosphamide 7Bevacizumab 7fludarabine phosphate 6Practice Guidelines as Topic 6Cetuximab 6Biopsy 6tislelizumab 5enzalutamide 5Trastuzumab 5Standard of Care 5Radiosurgery 5Magnetic Resonance Spectroscopy 5Dexamethasone 5Cytarabine 5tazemetostat 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × dexamethasone 21-phosphate × 90 days × Clear all
NCT03808610 2026-05-13

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
53 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡